Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Next CBD Product With False Claims Gets FTC Investigation, Not A Warning Letter

Sep 13 2019

• By Malcolm Spicer

WASHINGTON, DC - SEPTEMBER 28, 2013: Federal Trade Commission Building in Washington, DC.

Related Content

Safe Level For CBD As Dietary Ingredient? FDA Continues Data Review

Sep 13 2019

FTC Senses Cloud Around CBD Consumer Health Advertising, Warns More Firms

Sep 11 2019

Additional Topics

United States US States Dietary Supplements E-Commerce Advertising, Marketing & Sales Business Strategies Commercial Companies Compliance Distribution Enforcement FDA Ingredients Legal Issues Manufacturing Policy Regulation Safety Consumer

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window